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Case: A 9 year 3 month old girl is referred for concerns about early puberty. Her mother reports 
progressive breast development for at least a year along with adult body odor requiring deodorant 
use for the past 6 months. The mother has not noted any body hair, vaginal discharge or bleeding, 
but states that her daughter has been rapidly outgrowing shoes and clothing. There is no history of 
exogenous hormone exposure, and the child has otherwise been healthy. Past medical history 
reveals that the child was born at term with a birth weight of 7# 5oz and a length of 20 inches. 
Family history reveals that the mother is 5’3” and had menarche at age 12. The father is 5’7” and 
was an average age at the onset of puberty. The child is an honor-roll student in the 4th grade and 
lives at home with her parents and 6 year old brother. Review of systems reveals increased 
“moodiness” and is otherwise non-contributory. On physical exam, height is 140 cm (86th 
percentile) and weight is 44 kg (97th percentile). BMI is 22.4 kg/m2 (96th percentile, z-score 1.75). 
HEENT exam reveals a normal thyroid to palpation. Breasts are Tanner stage III-IV and no axillary 
hair is noted. GU exam reveals a normal female with pubic hair Tanner stage II and an estrogenized 
vaginal mucosa. A bone age x-ray is advanced at 12 years giving the child a predicted adult height 
(using the average Bayley-Pinneau Table)(1) of ~59”, compared with her target height of 62.5”. 
Having heard that early puberty will “stunt growth,” and concerned about her daughter’s ability to 
handle having periods, the mother requests that her child be treated to suppress puberty.  
Introduction 
This case represents a common reason for referral to the pediatric endocrine clinic. 
Although this child is within the normal range for the onset of puberty in girls, she has clearly had 
a rapid tempo of progression, and how has what is often characterized as a “poor” prognosis for 
adult height. Additional concerns include potential negative psychological consequences of being 
an early bloomer along with apprehensions about menarche, which seems imminent. The referral 
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by her primary care pediatrician is based on the presumption that stopping puberty will alleviate 
these concerns.  What is the evidence to support or refute this hope? 
Development of the long-acting analogs of gonadotropin releasing hormone (GnRHas) 
in the 1980’s revolutionized the treatment of central precocious puberty (CPP) worldwide (2-6). 
Since the advent of these drugs as first-line therapy for CPP, a plethora of GnRHas have been 
developed that utilize different routes of administration, employ unique delivery systems and have 
varying durations of action (7, 8). Given the undisputed success of GnRHas in the setting of CPP, 
it is not surprising that there has been sustained interest in the potential for their use beyond 
precocious puberty.  Indeed, continued linear growth well into young adulthood has long been 
recognized as a hallmark of untreated hypogonadotropic hypogonadism (9). Thus, the idea of 
rendering a child with normally timed puberty pharmacologically hypogonadal for the purposes of 
increasing adult height seems logical. Unfortunately, despite the anticipated benefit of putting 
puberty temporarily on hold in settings other than CPP, a meaningful increase in height has not 
generally been borne out by the studies conducted to date. Even among girls with CPP, a 
predictable and significant increase in adult stature occurs only in those who are treated at ≤ 6 
years, while those treated at between 6-8 years have a variable outcome(10). In contrast, no benefit 
in terms of height has been seen from the use of GnRHas in girls with CPP who are ≥ 8 years (11, 
12). Outside of precocious puberty, GnRHa treatment has also been investigated for use in children 
with short stature/poor predicted adult height, growth hormone deficiency, congenital adrenal 
hyperplasia, and profound primary hypothyroidism, in all cases also with the goal of increasing 
adult height. This paper will review the experience using GnRHas in each of these clinical 
situations with a focus on efficacy, safety and the risk/benefit ratio. An additional important 
consideration is the high cost of GnRHas, which approximate ~$20-$40k for two years of 
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treatment. Although beyond the scope of this review, GnRHas have been prescribed for 
considerations other than increasing height in children with developmental delay, gender 
dysphoria and in those undergoing genotoxic chemotherapy.  
GnRHas in Short Stature/Poor Predicted Adult Height 
 The most frequently explored indication for GnRHa therapy beyond precocious puberty 
has been in otherwise healthy children with a variety of forms of short stature or poor predicted 
adult height, as in our Case (13). Patient subgroups have included children with idiopathic/genetic 
short stature, those born small for gestational age, with early fast puberty and adopted girls. Several 
studies have been conducted during the last 20 years. Some of these have employed GnRHas as 
monotherapy while others have investigated the combination of GnRHas and growth hormone 
(GH) used simultaneously. Most sample sizes have ranged from <10-~40, and the duration of 
treatment has typically been anywhere from 2 to 4 years (14-16). Common limitations of existing 
trials have been a retrospective design, failure to include a control group, and/or mixed populations 
of subjects. In notable contrast to many other studies, a placebo-controlled trial of GnRHas in short 
adolescents with a variety of diagnoses was conducted, the results of which were published in 2003 
(17). In this rigorously designed trial, 47 adolescents with a low predicted adult height received a 
GnRHa or placebo for 3.5 years and were followed until linear growth was complete. A subset of 
patients in each group were also treated with GH. Although a 4.2 cm increase above the initial 
predicted height was seen in the experimental group, a significant decrement in bone mineral 
density compared with control was also noted. Thus, the authors concluded that using GnRHas to 
augment height in adolescents with normally-timed puberty is not a reasonable strategy.  
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Results from the combination of GnRHas and GH in the setting of short stature have 
been mixed.  However, few studies have been randomized and have followed children to adult 
height. While gains in height are often defined as the difference between predicted height at the 
start of treatment and achieved height, it is widely acknowledged that height prediction methods 
are flawed (18). Controlled studies have compared combination GnRHa and GH to either no 
treatment, GnRHa therapy alone or GH therapy alone. The heterogeneity in study design, along 
with the fact that the majority of treated subjects have been girls, renders it difficult to compare 
one trial to another and to derive firm conclusions. In studies to adult height, the benefit of 
combination therapy has ranged from 0-4 cm compared with controls and therefore even the most 
favorable outcomes have been of minimal magnitude (19-22). One of the arguably strongest 
studies undertaken to date randomly assigned 32 short adolescents with idiopathic short stature or 
born small for gestational age and early normal puberty to a GnRHa and GH or no treatment for 3 
years. While treated children achieved an adult height that was 4.9 cm above that predicted at 
baseline, no difference in final height between groups was seen (23). That 50% of the predicted 
height gain at discontinuation of treatment was lost during follow-up in the experimental group 
illustrates that height predictions tend to over predict height in children with short stature and early 
normal puberty, justifying use of the “average” rather than “accelerated” height prediction tables 
as in our Case. This study also found a trend toward lower bone mineral density at the lumbar 
spine, albeit one that did not reach statistical significance. On balance, no clear rationale exists for 
the use of GnRHas and GH in short children with on-time puberty.  
GnRHas in Growth Hormone Deficiency 
Children with growth hormone deficiency (GHD), particularly those diagnosed late, 
have been another population of interest in which to study the effect of GnRHas in addition to GH 
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to optimize adult height (24). A number of studies designed to address this possibility have been 
completed since the 1990’s. Here again we find few randomized trials, small sample sizes and a 
dearth of data regarding adult height (25, 26). Studies reporting benefit that followed subjects to 
final height show an increase of ~1-2 standard deviation scores (SDS) in height in the combination 
treatment group compared with GH alone(27, 28).  One such study randomized pubertal children 
with GHD to receive GH plus a GnRHa (n=7) or to receive GH alone (n=10) until a bone age of 
14 was reached in girls and of 16 was reached in boys. After 3 years of combined therapy, the 
group treated with GH plus a GnRHa had a notable decrease in the rate of skeletal maturation that 
translated into a near final height SDS that was significantly higher than that in the GH treatment 
alone group (-1.3 vs -2.7, p<0.05)(29).  While the experimental group was found to have a 
significantly lower bone mineral content at 3 years than subjects in whom physiologic puberty had 
been allowed to progress, the differences between groups had resolved by the time near final height 
was reached (30).  
Regrettably, not all studies have demonstrated such positive results.  A review of all 
patients with idiopathic GHD in the Kabi International Growth Study (KIGS) database who were 
also treated with GnRHas and had attained adult height was performed (31). In fact, the 39 
adolescents who had received combination therapy fared worse than the 1,893 treated with GH 
alone, with both boys and girls achieving a final height SDS below that reached by their 
counterparts who had gone through puberty normally. Given these conflicting results, it seems 
reasonable to conclude that the use of GnRHas in this setting should be limited to large-scale, 
prospective clinical trials.  
GnRHas in Congenital Adrenal Hyperplasia 
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It has long been recognized that children with classic congenital adrenal hyperplasia 
(CAH) are at risk for a significant loss of height potential and ultimate short stature (32). Individual 
patient characteristics that confer a higher likelihood of advanced skeletal maturation and earlier 
epiphyseal fusion include late diagnosis, poor control of CAH and development of secondary CPP 
(33). Thus far, a very limited number of studies have explored whether the addition of a GnRHa, 
typically combined with GH (above and beyond the standard medical treatment of CAH), might 
ameliorate the height deficit in these patients.  In one small study, 14 patients predicted to be >1 
SD below their target height were treated with a GnRHa and GH for four years. They achieved an 
adult height that was 1 SDS greater than a matched untreated historical control group(34).  A 
second non-randomized study by the same investigators offered GnRHa therapy as an adjunct to 
GH in children with CAH predicted to be short who had the onset of puberty at < age 10 in girls 
and < age 11 in boys. While an overall increase in achieved over baseline predicted adult height 
was seen, no difference in the outcome between those receiving a GnRHa and those treated with 
GH alone was found(35).  At this point, there appears to be no rationale for the use of GnRHas 
alone for the purpose of increasing adult height in children with CAH and normally-timed 
puberty(36).  
Secondary CPP refers to the early onset of central puberty that develops during treatment 
of peripheral precocious puberty (PPP), particularly in children with significantly advanced 
skeletal maturation at the time of diagnosis. . Several small studies have demonstrated a significant 
improvement in adult height in children with CAH and secondary CPP who were treated with a 
GnRHa (37-40). However, none have been randomized prospective trials, which likely explains 
why routine use of GnRHas to treat secondary CPP in children with CAH is not recommended by 
consensus guidelines (41). That being said, GnRHas are commonly used to treat secondary CPP 
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in other rare forms of PPP such as familial male limited precocious puberty and McCune-Albright 
syndrome(42). Since the physiology and treatment of abnormally early central puberty on the 
background of PPP is unlikely to be substantially different from that of CPP alone, the suggestion 
that GnRHas be prescribed in that situation only in the context of research is unlikely to be 
followed by clinicians and might be considered unduly restrictive.  
GnRHas in Profound Primary Hypothyroidism 
 A frequent consequence of longstanding severe hypothyroidism is a loss of height 
potential due to rapid bone age advancement that outpaces linear growth acceleration once 
treatment is initiated, particularly in peripubertal-aged children(43). Although GnRHa treatment 
has been postulated as one conceivable approach to prolong the opportunity for growth, most of 
the published reports in this area have been merely anecdotal (44-46). The studies that have been 
performed have been retrospective, and have failed to find any benefit from the addition of a 
GnRHa to levothyroxine in children with profound hypothyroidism (47, 48). Thus, there are 
insufficient data to conclude whether or not GnRHas have a place in the therapeutic 
armamentarium of children presenting with severe primary hypothyroidism. Rather, they should 
be used only in the context of prospective trials which can ultimately be used to inform clinical 
management.   
Safety and Psychological Concerns 
 GnRHas have an excellent track record of safety in the setting of CPP and are tolerated 
without difficulty in the vast majority of children. The most common adverse events associated 
with monthly and extended release injectable formulations are local site reactions such as sterile 
abscess formation (49). Difficulty with implant localization or breakage is the most frequent issue 
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encountered with the subcutaneous histrelin implant, which requires a minor surgical procedure 
usually performed using local anesthesia. Nonetheless, one cannot infer that the same safety profile 
exists when these medications are prescribed in on-time puberty versus in CPP. Even short term 
administration of a GnRHa to healthy young men causes extreme alterations in body composition, 
protein synthesis and calcium kinetics (50, 51). Of at least equal importance is the psychological 
impact of artificially manipulating the sex steroid milieu during adolescence. It is striking that 
published information on this aspect of GnRHa therapy beyond precocious puberty is virtually 
nonexistent. To the contrary, concerns about negative psychological sequelae of allowing early-
normal puberty to proceed unchecked are often voiced by parents and providers, and are likely 
based on the known association between high-risk behaviors and early maturation in girls (52). 
Whether treatment of on-time puberty with a GnRHa would alter this trajectory is unknown. Even 
among girls with CPP, no clear conclusions regarding psychological distress in either treated or 
untreated patients can be derived from existing studies (53, 54). This is an area in which more data 
are clearly needed.  
Consensus and Current Practice 
Cumulative experience to date regarding the effectiveness of GnRHas in increasing 
height in children with normally timed puberty is summarized in the Table. A 2009 international 
consensus conference on GnRHas concluded that their use in conditions other than CPP cannot be 
routinely suggested and that further investigation is needed (55). It is interesting to contemplate 
whether such position statements, which are based primarily on expert opinion, have any bearing 
on actual clinical practice. A review of GnRHa use at a large tertiary care center since 2009 
revealed that nearly one-third of the 260 patients in whom it had been prescribed did not meet 
criteria for CPP (56). Likely reasons for this include physicians’ anecdotal experiences of 
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perceived success in individual patients, and the pressure to “do something” when faced with a 
pubertal child whose height prediction falls well below the normal range. Since GnRHas are being 
used in the clinical domain for conditions other than precocious puberty and are often covered by 
insurers, there seems little incentive to hold out for objective evidence from clinical trials. 
Nevertheless, a collective entreaty to the pediatric endocrine community to embark on such trials, 
if successful, would simultaneously advance scientific knowledge and improve patient care. 
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Table: Effectiveness of GnRHas in conditions other than precocious puberty 
Indication Efficacy in Increasing 
Height 
Safety concerns Other Ref # 
Short 
stature/Poor 
predicted 
adult height 
• Minimal to no efficacy
when used alone in
short stature
• Minimal efficacy when
used in combination
with growth hormone
• Decreased
bone mineral
density
• Psychological
impact?
• Small sample
sizes
• Limited data on
adult height
• Mixed subjects
• 13-23
Growth 
Hormone 
Deficiency 
• Possible efficacy when
used in combination
with growth hormone
• Decreased
bone mineral
density
• Psychological
impact?
• Limited data on
adult height
• Conflicting
results; more
research needed
• 24-31
Congenital 
Adrenal 
Hyperplasia 
• No evidence of
efficacy when used
alone
• Possible efficacy when
combined with growth
hormone
• Likely effective in
secondary CPP
• Psychological
impact?
• No randomized
studies have
been conducted
• Not
recommended
by CAH practice
guidelines
• 32-42
Profound 
Primary 
Hypothyroi
dism 
• No evidence of
efficacy
• Psychological
impact?
• No randomized
studies have
been conducted
• 43-48
